Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | NOS2 | P35228 | 2/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | PDK1 | Q15118 | 14/20 | 0.49 |
| ▸ | ATF1 | P18846 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3061886 | 0.90 | PDK1 (0.50) | NOS3NOS1NOS2RAB9APDK1 | |
| SCHEMBL3060075 | 0.87 | GAA (0.53) | NOS3NOS1NOS2PDK1GAA | |
| SCHEMBL3052473 | 0.86 | NOS3 (0.61) | NOS3NOS1NOS2RAB9APDK1 | |
| SCHEMBL3056522 | 0.85 | ATF1 (0.57) | NOS3NOS1NOS2RAB9APDK1 | |
| SCHEMBL3043503 | 0.85 | PDK1 (0.51) | NOS3NOS1NOS2RAB9APDK1 | |
| SCHEMBL3054727 | 0.84 | GAA (0.53) | RAB9APDK1GAATSHR | |
| SCHEMBL3058307 | 0.84 | NOS3 (0.53) | NOS3NOS1NOS2PDK1 | |
| SCHEMBL3044246 | 0.84 | RAB9A (0.57) | NOS3NOS1NOS2RAB9APDK1 | |
| SCHEMBL3061617 | 0.83 | MAPK14 (0.50) | RAB9APDK1ATF1NFKB1GAA | |
| SCHEMBL3065409 | 0.83 | GAA (0.63) | RAB9APDK1GAATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | NOVARTIS AG (CH) | 2010-10-14 | — | — | US | disclosed |
| CN-101405268-A | Amide derivatives and their use for the treatment of protein-related diseases | NOVARTIS AG (CH) | 2009-04-08 | — | — | CN | disclosed |
| EP-2001851-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREAMENT OF G PROTEIN RELATED DISEASES | Novartis AG (CH) | 2008-12-17 | — | — | EP | disclosed |
| WO-2007110237-A2 | AMIDE DERIVATIVES AND THEIR APPLICATION FOR THE TREATMENT OF G PROTEIN RELATED DISEASES | NOVARTIS AG (CH) | 2007-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261758-A1 | HETEROCYCLIC AMIDES FOR USE AS PHARMACEUTICALS | HRH4, CNR1, CNR2 | NOS3 3019/4885NOS1 3682/4885NOS2 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.